Indication expansion now includes CAR‑T–associated severe or life-threatening CRS for adults and pediatric patients aged ≥2 years, supporting guideline-concordant IL‑6 receptor blockade in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results